Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
Full metadata record
|dc.identifier.citation||Supportive Care in Cancer, 2007; 15(5):483-490||-|
|dc.description.abstract||Background With the increased use of so-called targeted anti-cancer therapies, there has been a change in toxicities that patients are experiencing. As most targeted therapies are given in conjunction with more traditional chemotherapeutic agents, toxicities of these combination therapies are also evolving. Whilst we increasingly understand the mechanisms underlying the toxicities of chemotherapy and radiotherapy, the addition of targeted treatments requires a new understanding of both toxicity and interacting mechanisms. Aims The aims of this review (which formed the basis of an invited plenary lecture at the 2006 Annual conference of the Multinational Association of Supportive Care in Cancer) were to define targeted anti-cancer therapy, to describe its known impact on the mucosa, either alone, or in combination with chemotherapy with or without radiotherapy, and finally to provide an outline for future directions in research into mucosal injury from targeted anti-cancer therapies. Methodology Two separate literature reviews were conducted. The combined reviews produced 700 papers of which approximately 70 were included in the review. Results As with mucosal injury (or mucositis) in general, the studies are hampered by a lack of mucosal injury as primary endpoint, and the variable definitions and levels of reporting. The depth to which mucosal injury was studied was also inadequate. However, it is clear that the key to understanding toxicity is to understand the mechanism of action of the drug, from which it should be possible to predict the toxicities that will occur. Conclusions With the increasing use of targeted anti-cancer therapies, mucosal injury, particularly in its manifestations of diarrhoea, and mouth ulcers, is becoming even more prominent. More publications of basic and clinical research in this area is required.||-|
|dc.subject||Targeted anti-cancer therapy||-|
|dc.title||Mucosal injury from targeted anti-cancer therapy||-|
|dc.contributor.organisation||Department of Medical Oncology, Royal Adelaide Hospital||-|
|dc.identifier.orcid||Keefe, D. [0000-0001-9377-431X]||-|
|dc.identifier.orcid||Gibson, R. [0000-0002-4796-1621]||-|
|Appears in Collections:||Aurora harvest 6|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.